Skip to main content
SpringerLink
Log in

The VA Co-operative Studies; The First RCTs in Cardiovascular Disease – A Tribute to Edward D. Freis

  • Chapter
  • First Online:
Management of Hypertension

  • 1037 Accesses

Abstract

The relationship between elevated blood pressure and premature death was first demonstrated from data collected by insurance companies in the 1920s [1], and the association continued to be strengthened by data from the same source accumulated over the next 3 decades. The beneficial effects of blood pressure reduction however, remained controversial till the mid 1950s because of the luck of effective therapies and the fear of harming vital organs and actually increasing cardiovascular events with lower pressures [2]. Thus therapeutic nihilism prevailed for a long time.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hunter ARO. Mortality study of impaired lives. Actuarial Soc. 1923;24:453–6.

    Google Scholar 

  2. Perera GA. Hypertensive vascular disease: description and natural history. J Chronic Dis. 1955;1:33–42.

    Article  CAS  Google Scholar 

  3. Doumas M, Papademetriou V, Douma S, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens. 2010;2011:318549.

    PubMed  PubMed Central  Google Scholar 

  4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA. 1967;202:1028–34.

    Article  Google Scholar 

  5. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143–52.

    Article  Google Scholar 

  6. Freis E. Hypertension treatment: contributions and comments on challenges. J Clin Hypertens. 2004;6:45–6.

    Article  Google Scholar 

  7. Goldring W, Chasis H, Schreiner GE, Smith HW. Reassurance in the management of benign hypertensive disease. Circulation. 1956;14:260–4.

    Article  Google Scholar 

  8. Kempner W. Treatment of hypertensive vascular disease with rice diet. Am J Med. 1948;4:545–77.

    Article  CAS  Google Scholar 

  9. Goldring W, Chasis H, Fishberg AM, et al. Hypertensive vascular disease; transcription of a panel meeting on therapeutics. Bull N Y Acad Med. 1954;30:376–98.

    CAS  PubMed  Google Scholar 

  10. Adson AW, McCraig W, Brown GE. Surgery in its relation to hypertension. Surg Gynecol Obstet. 1936;62:314–31.

    Google Scholar 

  11. Peet MM. Hypertension and its surgical treatment by supradiaphragmatic splanchnicectomy. Am J Surg. 1948;LXXV:48–68.

    Article  Google Scholar 

  12. Papademetriou V, Doumas M, Tsioufis C. Renal sympathetic denervation for the treatment of difficult to control or resistant hypertension. Int J Hypertens. 2011;2011:196518.

    PubMed  PubMed Central  Google Scholar 

  13. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.

    Article  Google Scholar 

  14. Doumas M, Douma S. Interventional management of resistant hypertension. Lancet. 2009;373:1228–30.

    Article  Google Scholar 

  15. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.

    Article  Google Scholar 

  16. Doumas M, Douma S. Renal sympathetic denervation: the jury is still out. Lancet. 2010;376:1878–80.

    Article  Google Scholar 

  17. Tsioufis C, Dimitriadis K, Kordalis A, et al. Renal denervation therapy: can it contribute to better blood pressure control in hypertension? Curr Vasc Pharmacol. 2017;16:66–9. https://doi.org/10.2174/15701611156661704226151649.

    Article  PubMed  Google Scholar 

  18. Tsioufis C, Dimitriadis K, Thomopoulos C, et al. Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Curr Vasc Pharmacol. 2014;12:55–62.

    Article  CAS  Google Scholar 

  19. Faselis C, Doumas M, Kokkinos P, Tsioufis C, Papademetriou V. The role of renal nerve ablation for the management of resistant hypertension and other disease conditions: benefits and concerns. Curr Vasc Pharmacol. 2014;12:38–46.

    Article  CAS  Google Scholar 

  20. Raman VK, Tsioufis C, Doumas M, Papademetriou V. Renal denervation therapy for drug-resistant hypertension: does it still work? Curr Treat Options Cardiovasc Med. 2017;19:39.

    Article  Google Scholar 

  21. Papademetriou V, Doumas M, Anyfanti P, Faselis C, Kokkinos P, Tsioufis C. Renal nerve ablation for hypertensive patients with chronic kidney disease. Curr Vasc Pharmacol. 2014;12:47–54.

    Article  CAS  Google Scholar 

  22. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation in hypertension. Curr Opin Nephrol Hypertens. 2011;20:647–53.

    Article  Google Scholar 

  23. Doumas M, Athyros V, Karagiannis A. Transcatheter renal sympathetic denervation: chasing a chimera or a matter of technological improvements. Cardiology. 2015;131:186–8.

    Article  Google Scholar 

  24. Doumas M, Lazaridis A, Papademetriou V. Renal nerve ablation for resistant hypertension: the dust has not yet settled. J Clin Hypertens. 2014;16:399–400.

    Article  Google Scholar 

  25. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012;30:874–6.

    Article  CAS  Google Scholar 

  26. Doumas M, Faselis C, Kokkinos P, Tsioufis C, Papademetriou V. Clinical studies of renal nerve ablation. Unanswered questions for its efficacy and safety. Curr Clin Pharmacol. 2013;8:212–6.

    Article  Google Scholar 

  27. Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension. 2011;58:e19.

    Article  CAS  Google Scholar 

  28. Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension. Eur Heart J. 2013;34:2132–40.

    Article  CAS  Google Scholar 

  29. Papademetriou V, Doumas M, Tsioufis C. Renal sympathetic denervation: hibernation or resurrection? Cardiology. 2016;135:87–97.

    Article  Google Scholar 

  30. Papademetriou V, Rashidi AA, Tsioufis C, Doumas M. Renal nerve ablation for resistant hypertension: how did we get here, present status and future directions. Circulation. 2014;129:1440–51.

    Article  Google Scholar 

  31. Bhatt DL, Kandzari DE, O’Neill WW, Symplicity HTN-3 Investigators, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.

    Article  CAS  Google Scholar 

  32. Papademetriou V, Tsioufis C, Doumas M. Renal denervation and Symplicity HTN-3: “Dubium sapientiae initium” (doubt is the beginning of wisdom). Circ Res. 2014;115:211–4.

    Article  CAS  Google Scholar 

  33. Tsioufis C. Hypertension: is the sham-procedure ‘toxic’ for renal denervation? Nat Rev Nephrol. 2014;10:186–7.

    Article  Google Scholar 

  34. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomized, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–70. https://doi.org/10.1016/S0140-6736(17)32281-X.

    Article  PubMed  Google Scholar 

  35. Perera GA. Antihypertensive drug versus symptomatic treatment in primary hypertension: effect on survival. J Am Med Assoc. 1960;173:11–3.

    Article  CAS  Google Scholar 

  36. Schoenberger JA, Stamler J, Shekelle RB, Shekelle S. Current status of hypertension control in an industrial population. JAMA. 1972;222:559–62.

    Article  CAS  Google Scholar 

  37. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-Up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562–71.

    Google Scholar 

  38. Management Committee of the Australian National Blood Pressure Study. The Australian therapeutic trial in mild hypertension. Lancet. 1980;1:1261–7.

    Google Scholar 

  39. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97–104.

    Article  Google Scholar 

  40. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.

    Article  Google Scholar 

  41. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.

    Article  CAS  Google Scholar 

  42. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.

    Article  Google Scholar 

  43. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Task Force Members, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.

    Article  CAS  Google Scholar 

  44. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.

    Article  CAS  Google Scholar 

  45. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, CHEP Guidelines Task Force, et al. Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32:569–88.

    Article  Google Scholar 

  46. Moser M. Salute to the icons of hypertension. J Clin Hypertens. 2004;6:8–9.

    Article  Google Scholar 

  47. Freis ED. The Veterans Administration cooperative study on antihypertensive agents. Implications for stroke prevention. Stroke. 1974;5:76–7.

    Article  CAS  Google Scholar 

  48. Freis ED. Reminiscences of the Veterans Administration Trial of the treatment of hypertension. Hypertension. 1990;16:472–5.

    Article  CAS  Google Scholar 

  49. Veterans Administration Cooperative Study on Antihypertensive Agents. A double blind control study of antihypertensive agents: I. Comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, chlorisondamine, mecamylamine, and pentolinium tartrate. Arch Intern Med. 1960;106:81–96.

    Article  Google Scholar 

  50. Veterans Administration Cooperative Study on Antihypertensive Agents. Double blind control study of antihypertensive agents: II. Further report on the comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, chlorisondamine, mecamylamine, and pentolinium tartrate. Arch Intern Med. 1962;110:126–33.

    Google Scholar 

  51. Freis ED, Stanton JR. A clinical evaluation of veratrum viride in the treatment of essential hypertension. Am Heart J. 1948;36:723–38.

    Article  CAS  Google Scholar 

  52. Freis ED, Stanton JR. The hemodynamic effects of hypotensive drugs in man; dihydroergocomine. J Clin Invest. 1949;28:1387–402.

    Article  CAS  Google Scholar 

  53. Finnerty FA, Fries ED. Experimental and clinical evaluation in man of hexamethonium (C6), a new ganglionic blocking agent. Circulation. 1950;2:828–36.

    Article  CAS  Google Scholar 

  54. Freis ED, Rose JC, Higgins TF, et al. The hemodynamic effects of hypotensive drugs in man. IV. 1-Hydralazinophthalazine. Circulation. 1953;8:199–204.

    Article  CAS  Google Scholar 

  55. Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. J Am Med Assoc. 1958;166:137–40.

    Article  CAS  Google Scholar 

  56. Freis ED, Wanko A, Wilson IM, Parrish AE. Chlorothiazide in hypertensive and normotensive patients. Ann N Y Acad Sci. 1958;71:450–5.

    Article  CAS  Google Scholar 

  57. Frohlich ED, Schnaper HW, Wilson IM, Freis ED. Hemodynamic alterations in hypertensive patients due to chlorothiazide. N Engl J Med. 1960;262:1261–3.

    Article  CAS  Google Scholar 

  58. The SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015;373:2103–16.

    Article  Google Scholar 

  59. SPRINT Research Group. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. Ann Intern Med. 2017;167:375–83. https://doi.org/10.7326/M16-2966.

    Article  Google Scholar 

  60. SPRINT Research Group. Effect of intensive blood pressure treatment on patient-reported outcomes. N Engl J Med. 2017;377:733–44.

    Article  Google Scholar 

  61. SPRINT Research Group. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial. Diabetes Care. 2017;40:1401–8. https://doi.org/10.2337/dc17-0885.

    Article  CAS  Google Scholar 

  62. Stergiou GS, Doumas M, Kollias A, Papademetriou V. Important practice lessons from the SPRINT study beyond the blood pressure goal: all well known and now confirmed. J Am Soc Hypertens. 2016;10:613–7.

    Article  Google Scholar 

  63. Freis ED, Wilkins RW. The effects of pentaquine in patients with hypertension. Proc Soc Exp Biol Med. 1947;64:455–8.

    Article  CAS  Google Scholar 

  64. Wilkins RW. New drug therapies in arterial hypertension. Ann Intern Med. 1952;37:1144–55.

    Article  CAS  Google Scholar 

  65. Wilkins RW, Judson WE. The use of Rauwolfia serpentina in hypertensive patients. N Engl J Med. 1953;248:48–53.

    Article  CAS  Google Scholar 

  66. Freis ED, Wilson IM. Potentiating effect of chlorothiazide (Diuril) in combination with antihypertensive agents: preliminary report. Med Ann Dist Columbia. 1957;26:468–71.

    PubMed  Google Scholar 

  67. Hollander W, Wilkins RW. Chlorothiazide: a new type of drug for the treatment of arterial hypertension. BMQ. 1957;8:69–75.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Georgetown University and VA Medical Center, Washington, DC, USA

    Vasilios Papademetriou

  2. VA Medical Center and George Washington University, Washington, DC, USA

    Michael Doumas & Charles Faselis

  3. VA Medical Center and Georgetown University, Washington, DC, USA

    Costas Tsioufis

  4. 1st Academic Department of Cardiology, Athens, Greece

    Costas Tsioufis & Kyriakos Dimitriadis

Authors
  1. Vasilios Papademetriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Doumas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Costas Tsioufis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyriakos Dimitriadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles Faselis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasilios Papademetriou .

Editor information

Editors and Affiliations

  1. Georgetown University and VA Medical Center, Washington, DC, USA

    Vasilios Papademetriou

  2. Fourth Internal Medicine Department, Evangelismos State General Hospital, Athens, Greece

    Emmanuel A. Andreadis

  3. Fourth Internal Medicine Department, Evangelismos State General Hospital, Athens, Greece

    Charalampia Geladari

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Papademetriou, V., Doumas, M., Tsioufis, C., Dimitriadis, K., Faselis, C. (2019). The VA Co-operative Studies; The First RCTs in Cardiovascular Disease – A Tribute to Edward D. Freis. In: Papademetriou, V., Andreadis, E., Geladari, C. (eds) Management of Hypertension. Springer, Cham. https://doi.org/10.1007/978-3-319-92946-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92946-0_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92945-3

  • Online ISBN: 978-3-319-92946-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation